key: cord-1001834-o7qfgb73
authors: Tahir, A.; Sohail, Z.; Nasim, B.; Parmar, N.V.
title: Widespread cutaneous small vessel vasculitis secondary to COVID‐19 infection
date: 2020-08-15
journal: Int J Dermatol
DOI: 10.1111/ijd.15106
sha: 251bf6aa8aaba6398ac1450f09efcc4aea94c81f
doc_id: 1001834
cord_uid: o7qfgb73

nan

Vascular damage in COVID-19 infection is postulated to occur due to immune response against viral antigen deposition. 5 The current hypothesis involves angiotensin II. The receptor of SARS-CoV-2 virus, angiotensin converting enzyme (ACE) 2, is present on vascular endothelial cells in addition to alveolar pneumocytes. 6 Binding and inhibition of ACE2 by SARS-CoV-2 leads to increased angiotensin II levels and resultant vasoconstriction, endothelial dysfunction, and thrombosis. 6 Our patient was a previously healthy man who developed widespread targetoid plaques with central necrosis, palpable purpura, and oral lesions as the initial manifestation of COVID-19 infection prior to respiratory symptoms. Viral clearance was complemented by gradual resolution of skin lesions. Although cases of CSVV have been recently reported, our case is unique as the skin biopsy revealed microthrombi in dermal capillaries thus adding evidence to the current premise on COVID-19 pathogenesis.

In summary, we describe a patient with CSVV as the chief manifestation of COVID-19 infection with mild respiratory involvement. Physicians should be aware that in the era of the 

Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients

Vascular skin symptoms in COVID-19: a french observational study

SARS-Coronavirus-2 and acute urticaria

Varicella-like exanthem as a specific COVID-19 associated skin manifestation: multicenter case series of 22 patients

Cutaneous small vessel vasculitis secondary to COVID-19 infection: a case report

Renin-angiotensinaldosterone system inhibitors in patients with Covid-19